Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02239510 · ClinicalTrials.gov registry record · NA

Efficacy of Linaclotide to Senna for CIC

A NA study, sponsored by TriHealth.

Terminated
Registry status
NA
Development phase
9
Enrollment target

NCT02239510 is a NA study that was terminated before completion, run by TriHealth. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02239510, a NA study, was terminated before completion, sponsored by TriHealth.

TERMINATED
Registry status
NA
Development phase
9 participants
Enrollment target

Study Summary

In this prospective, randomized, double blind study, the aim is to determine the efficacy of Linaclotide in relation to Senna in relieving the symptoms of chronic idiopathic constipation (CIC). Patients with CIC, (age 18 - 70) will be enrolled in the study and randomized to Senna or Linaclotide. Patients will be asked to complete questionnaires during the study and will be followed for 12 weeks. Main outcomes include number of daily bowel movements and measures from surveys regarding bowel habits, relief, and satisfaction.

Interventions

  • DRUG Senna
  • DRUG Linzess

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2014-09
Est. Completion 2016-06
Phase NA

Sponsor

TriHealth

81 total trials

What the Registry Record Tells You About NCT02239510

The ClinicalTrials.gov registry entry for NCT02239510 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Senna is the first listed.

NCT02239510 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02239510 about?

NCT02239510 is a clinical study titled "Efficacy of Linaclotide to Senna for CIC". In this prospective, randomized, double blind study, the aim is to determine the efficacy of Linaclotide in relation to Senna in relieving the symptoms of chronic idiopathic constipation (CIC). Patients with CIC, (age 18 - 70) will be enrolled in the study and randomized to Senna or Linaclotide. Pat...

What is the current status of trial NCT02239510?

This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2014-09. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02239510?

The interventions under investigation include: Senna (DRUG), Linzess (DRUG).

Who is sponsoring clinical trial NCT02239510?

This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.